دورية أكاديمية
أعرض في EDS

TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress.

التفاصيل البيبلوغرافية
العنوان: TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress.
المؤلفون: Ueno H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan. h-ueno@taiho.co.jp., Hoshino T; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Yano W; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Tsukioka S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Suzuki T; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Hara S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Ogino Y; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Chong KT; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Suzuki T; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Tsuji S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Itadani H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Yamamiya I; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Otsu Y; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Ito S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Yonekura T; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Terasaka M; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Tanaka N; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Miyahara S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan. sei-miyahara@taiho.co.jp.
المصدر: Communications biology [Commun Biol] 2022 Jun 09; Vol. 5 (1), pp. 571. Date of Electronic Publication: 2022 Jun 09.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group UK Country of Publication: England NLM ID: 101719179 Publication Model: Electronic Cited Medium: Internet ISSN: 2399-3642 (Electronic) Linking ISSN: 23993642 NLM ISO Abbreviation: Commun Biol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London, United Kingdom : Nature Publishing Group UK, [2018]-
مواضيع طبية MeSH: Antineoplastic Agents*/pharmacology , Enzyme Inhibitors*/pharmacology , Ribonucleotide Reductases*/antagonists & inhibitors, Animals ; DNA Replication ; Humans ; Nuclear Proteins/metabolism
مستخلص: Ribonucleotide reductase (RNR) is composed of two non-identical subunits, R1 and R2, and plays a crucial role in balancing the cellular dNTP pool, establishing it as an attractive cancer target. Herein, we report the discovery of a highly potent and selective small-molecule inhibitor, TAS1553, targeting protein-protein interaction between R1 and R2. TAS1553 is also expected to demonstrate superior selectivity because it does not directly target free radical or a substrate binding site. TAS1553 has shown antiproliferative activity in human cancer cell lines, dramatically reducing the intracellular dATP pool and causing DNA replication stress. Furthermore, we identified SLFN11 as a biomarker that predicts the cytotoxic effect of TAS1553. Oral administration of TAS1553 demonstrated robust antitumor efficacy against both hematological and solid cancer xenograft tumors and also provided a significant survival benefit in an acute myelogenous leukemia model. Our findings strongly support the evaluation of TAS1553 in clinical trials.
(© 2022. The Author(s).)
References: Nat Rev Cancer. 2015 Sep;15(9):528-39. (PMID: 26299592)
J Mol Biol. 1969 Nov 28;46(1):39-55. (PMID: 4902212)
FEBS Lett. 1990 Oct 15;272(1-2):61-4. (PMID: 2226836)
J Med Chem. 2018 Feb 8;61(3):666-680. (PMID: 29253340)
Nat Commun. 2017 Aug 14;8(1):241. (PMID: 28808226)
Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9815-20. (PMID: 21628579)
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):271-81. (PMID: 21460445)
Mol Cell Biochem. 1994 Nov 9;140(1):1-22. (PMID: 7877593)
Oncotarget. 2016 Sep 27;7(39):63003-63019. (PMID: 27557498)
Br J Cancer. 2007 Oct 8;97(7):888-94. (PMID: 17848949)
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3. (PMID: 15299374)
Adv Enzyme Regul. 2005;45:112-25. (PMID: 16054677)
Nat Commun. 2014;5:3128. (PMID: 24451681)
J Med Chem. 2008 Aug 14;51(15):4653-9. (PMID: 18610997)
Cancer Chemother Pharmacol. 2010 Mar;65(4):679-86. (PMID: 19639316)
J Biol Chem. 2004 Jun 25;279(26):27030-8. (PMID: 15096505)
J Enzyme Inhib Med Chem. 2019 Dec;34(1):438-450. (PMID: 30734609)
Mol Cancer Ther. 2018 Aug;17(8):1648-1658. (PMID: 29748209)
J Clin Oncol. 2018 Aug 10;36(23):2386-2394. (PMID: 29906251)
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55. (PMID: 15299926)
Sci Rep. 2017 Apr 13;7:46380. (PMID: 28406179)
Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14324-9. (PMID: 17726094)
J Gastroenterol. 2007 May;42(5):389-94. (PMID: 17530364)
Biochem Pharmacol. 2005 Feb 15;69(4):627-34. (PMID: 15670581)
J Med Chem. 2001 Jan 4;44(1):36-46. (PMID: 11141086)
J Virol. 1998 Oct;72(10):7941-9. (PMID: 9733832)
Nature. 2000 Mar 2;404(6773):42-9. (PMID: 10716435)
J Med Chem. 2015 Dec 24;58(24):9498-509. (PMID: 26488902)
Nat Med. 2017 Feb;23(2):250-255. (PMID: 27991919)
Nat Rev Cancer. 2015 May;15(5):276-89. (PMID: 25907220)
Cancer Res. 2003 Jun 1;63(11):2802-11. (PMID: 12782585)
Int J Oncol. 2006 Feb;28(2):469-78. (PMID: 16391803)
Nat Rev Drug Discov. 2016 Nov 3;15(11):735-737. (PMID: 27807357)
Pharm Res. 2009 Jun;26(6):1504-15. (PMID: 19291372)
Biochem Pharmacol. 2007 May 15;73(10):1548-57. (PMID: 17324380)
J Clin Oncol. 1983 Sep;1(9):546-51. (PMID: 6583325)
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15030-5. (PMID: 22927417)
PLoS One. 2015 May 22;10(5):e0127600. (PMID: 26001082)
Cancer Res. 2008 Apr 15;68(8):2652-60. (PMID: 18413732)
Expert Opin Ther Targets. 2013 Dec;17(12):1423-37. (PMID: 24083455)
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501. (PMID: 20383002)
Cancer Res. 2004 Jan 1;64(1):1-6. (PMID: 14729598)
Nature. 1986 May 22-28;321(6068):439-41. (PMID: 3012359)
Mol Cancer Ther. 2018 Aug;17(8):1683-1693. (PMID: 29748212)
J Biol Chem. 1981 Sep 25;256(18):9436-40. (PMID: 6270086)
Nat Rev Drug Discov. 2013 Jun;12(6):447-64. (PMID: 23722347)
Pharmacol Ther. 2019 Sep;201:94-102. (PMID: 31128155)
Ann Oncol. 2006 May;17 Suppl 5:v7-12. (PMID: 16807468)
Future Oncol. 2012 Feb;8(2):145-50. (PMID: 22335579)
Nat Struct Mol Biol. 2011 Mar;18(3):316-22. (PMID: 21336276)
Mol Cell. 2018 Feb 1;69(3):371-384.e6. (PMID: 29395061)
N Engl J Med. 2008 Mar 27;358(13):1362-9. (PMID: 18367739)
Biochemistry. 2016 Jan 19;55(2):373-81. (PMID: 26727048)
Nature. 1986 May 22-28;321(6068):441-3. (PMID: 3012360)
Cancer Res. 2013 Nov 1;73(21):6484-93. (PMID: 24072748)
Cell Res. 2015 Jan;25(1):9-23. (PMID: 25403473)
Nat Biotechnol. 2013 Jun;31(6):522-9. (PMID: 23604282)
Oncogene. 2015 Apr 16;34(16):2011-21. (PMID: 24909171)
Cell Oncol (Dordr). 2019 Apr;42(2):117-130. (PMID: 30446944)
Eur J Biochem. 1969 Jul;9(4):561-73. (PMID: 4896737)
Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8241-8246. (PMID: 28716944)
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Enzyme Inhibitors)
0 (Nuclear Proteins)
0 (SLFN11 protein, human)
EC 1.17.4.- (Ribonucleotide Reductases)
تواريخ الأحداث: Date Created: 20220610 Date Completed: 20220613 Latest Revision: 20220812
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9184620
DOI: 10.1038/s42003-022-03516-4
PMID: 35681099
قاعدة البيانات: MEDLINE
الوصف
تدمد:2399-3642
DOI:10.1038/s42003-022-03516-4